Previous 10 | Next 10 |
BASEL, LONDON, and NEW YORK, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Monday, November 13, 2023, to report its financial results for the second quarter ended September 30, 2023, and provide a b...
2023-10-28 07:33:42 ET Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha , iTunes , Spotify . For further details see: Wall Street Breakfast: What Moved Markets
2023-10-24 09:25:49 ET Summary Roche Holding AG acquires Telavant Holdings for $7.1B upfront and $150M milestone payment, potentially very interesting deal. Roivant Sciences owns a 75% equity interest in Telavant Holdings. Curiously, Roivant Sciences stock sold off on the news...
2023-10-23 07:30:26 ET Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha , iTunes , Spotify . For further details see: Wall Street Breakfast: Opening The Books
2023-10-23 06:42:07 ET Summary Roivant Sciences announces $7.1B deal with Roche to acquire Telavant and its new bowel disease therapy. Stonepeak to acquire Textainer Group for $2.1B. Japan's competition watchdog to investigate Google over antimonopoly practices related to its ...
2023-10-23 05:32:56 ET Stock futures fell slightly in premarket trading on Monday as U.S. Treasury yields remained near multiyear highs amid investor concerns about rising interest rates ahead of big tech earnings reports. For further details see: Biggest stock movers today: Crypto-...
2023-10-23 03:10:38 ET More on Roche, Roivant Sciences Skin In The Game: Behind Roivant's Significant Rise Be Patient, Roche Is A Clear Buy At This Price Roche: Positive Readouts From Pipeline Roche: 2023 Should Mark The Bottom Roche slips after in-li...
Roche will gain the rights to develop, manufacture and commercialize RVT-3101 in the US and Japan for the treatment of inflammatory bowel disease and potentially multiple other diseases RVT-3101 is a Phase 3-ready antibody with first-in-class and best-in-disease potential, a novel mode of act...
2023-10-13 08:10:01 ET More on Roivant Sciences Skin In The Game: Behind Roivant's Significant Rise Immunovant to raise $450M from public offering and private placement Immunovant stock rallies for second day, fueled by public offering, drug data For further ...
BOSTON, Oct. 13, 2023 (GLOBE NEWSWIRE) -- Covant Therapeutics, an innovative covalent drug discovery company, is pleased to announce the appointment of Vincent Hennemand as Chief Executive Officer (CEO). Vincent Hennemand is a seasoned executive with a distinguished career in the pharmaceutic...
News, Short Squeeze, Breakout and More Instantly...
Roivant Sciences Ltd. Company Name:
ROIV Stock Symbol:
NASDAQ Market:
Roivant Sciences Ltd. Website:
2024-06-02 17:44:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
BASEL, Switzerland and LONDON and NEW YORK, May 30, 2024 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today reported its financial results for the fourth quarter and fiscal year ended March 31, 2024, and provided a business update. Once-daily brepocitinib produced the best Treatment Failure...
BASEL, Switzerland and LONDON and NEW YORK, May 16, 2024 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, May 30, 2024, to report its financial results for the fourth quarter and fiscal year ended March 31...